



Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

Kenichi Inoue¹  · Jun Ninomiya² · Tsuyoshi Saito³ · Katsuhiko Okubo⁴ · Takashi Nakakuma⁵ · Hirofumi Yamada⁶ · Kei Kimizuka⁷ · Tohru Higuchi³ · for the SBCCSG-36 investigators

Published online: 25 April 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Correction to: Investigational New Drugs

<https://doi.org/10.1007/s10637-019-00755-x>

The authors would like to note the replacement of Fig. 2b, for which Fig. 2a was placed erringly, with appropriate Fig. 2b.

The original article has been corrected.

The online version of the original article can be found at <https://doi.org/10.1007/s10637-019-00755-x>

✉ Kenichi Inoue
ino.bad.ken@gmail.com

¹ Division of Breast Oncology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita-adachi-gun, Saitama 362-0806, Japan

² Department of Breast Surgery, Ninomiya Hospital, Soka, Japan

³ Department of Breast Surgery, Saitama Red Cross Hospital, Saitama, Japan


⁴ Department of Breast Unit, Toda Central General Hospital, Saitama, Japan

⁵ Department of Breast Surgery, Ageo Central General Hospital, Ageo, Japan

⁶ Department of Surgery, Sekishindo Hospital, Saitama, Japan

⁷ Department of Breast Surgery, Kasukabe Medical Center, Kasukabe, Japan

Fig. 2 **a** Time to treatment failure with eribulin. **b** Time to treatment failure with trastuzumab and pertuzumab



Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.